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Edited by Laszlo NagyAbstract Insulin production aﬀorded by hepatic gene therapy
(HGT) retains promise as a potential treatment for type 1 diabe-
tes, but successful approaches have been limited. We employed a
novel and previously untested promoter for this purpose, glucose
transporter-2 (GLUT2) to drive insulin production via delivery
by recombinant adeno-associated virus (rAAV). In vitro, the
GLUT2 promoter was capable of robust glucose-responsive
expression in transduced HepG2 human hepatoma cells. There-
fore, rAAV constructs were designed to express the furin-cleav-
able human preproinsulin B10 gene, under the control of the
murine GLUT2 promoter and packaged for delivery with rAAV
expressing the type 5 capsid. Streptozotocin-induced diabetic
mice were subjected to hepatic portal vein injection immediately
followed by implantation of a sustained-release insulin pellet to
allow time for transgenic expression. All mice injected with the
rAAV5-GLUT2-fHPIB10 virus remained euglycemic for up to
35 days post-injection, with 50% euglycemic after 77 days
post-injection. In contrast, mock-injected mice became hypergly-
cemic within 15 days post-injection following dissolution of the
insulin pellet. Serum levels of both human insulin and C-peptide
further conﬁrmed successful transgenic delivery by the rAAV5-
GLUT2-fHPIB10 virus. These ﬁndings indicate that the GLUT2
promoter may be a potential candidate for regulating transgenic
insulin production for hepatic insulin gene therapy in the treat-
ment of type I diabetes.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Type 1 diabetes is characterized by the progressive loss of
insulin production due to the autoimmune destruction of pan-
creatic b-cells [1]. Although islet cell transplantation appears
promising as a treatment for type 1 diabetes, some limitations
include immune rejection and the lack of an adequate supply
of transplant-quality islets for the treatment of patients with
the disease [2,3]. Gene therapy represents another potential*Corresponding author. Present address: Childrens Hospital of
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production aﬀorded by viral gene delivery providing an exam-
ple of one such eﬀort [4,5]. Several groups have investigated
the liver as a site and source of transgenic insulin production
[6–16]. In order for hepatic insulin gene therapy (HIGT) to
be successful, transgenic insulin production must be tightly
coupled to glucose concentration. The liver provides an excel-
lent surrogate organ for transgenic insulin production since,
similar to pancreatic b-cells, it has the ability to rapidly adapt
to blood glucose concentrations due to its pivotal role in
maintaining glucose homeostasis [17]. Indeed, the liver pos-
sesses glucose-sensing components, such as glucokinase and
the glucose transporter 2 (GLUT2) [18]. A highly eﬃcient
way of controlling hepatic insulin production would, in theory,
involve the use of these glucose-controlling systems. However,
the major characteristic of hepatocytes that has been the true
‘‘Achilles heel’’ for successful HIGT has involved the lack of
a regulated secretory protein pathway. In contrast to the pulsi-
tile and regulated insulin secretion of islets, hepatocytes can
only constitutively secrete proteins. Therefore, transgenic he-
patic insulin production must be heavily regulated at the tran-
scriptional level, which places utmost importance on the
promoter utilized to regulate hepatic transgenic insulin
production.
GLUT2 is a facilitative glucose transporter found primarily
in the liver and pancreatic b-cells [19]. The regulation of
GLUT2 in the liver is controlled by the promoter region and
highly coupled to various metabolic states. Multiple studies
have demonstrated that liver GLUT2 expression is upregu-
lated in a dose-dependant manner according to glucose con-
centration in primary rat hepatocytes and hepatocyte cell
lines [20–22]. Also, liver GLUT2 expression is decreased dur-
ing starvation and increased to normal levels post-refeeding
of fasted rats [23]. In diabetic rats, liver GLUT2 expression
is increased, but is corrected to normal levels when hyperglyce-
mic conditions are corrected by exogenous insulin [24]. All of
these data strongly suggest that liver GLUT2 expression is
stimulated by glucose and downregulated by insulin both
in vivo and in vitro. GLUT2 has also been suggested to serve
as the actual glucose sensor in the liver portal vein indicating
its essential nature for the rapid glucose response of that organ
[25,20]. Furthermore, GLUT2 is regulated solely at the tran-
scriptional level by the promoter region and yet is capable of
a rapid, dose-dependent glucose-response in the liver [20]. All
of these characteristics indicate that the GLUT2 promoteration of European Biochemical Societies.
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insulin gene therapy. However, the GLUT2 promoter has yet
to be evaluated for this purpose and this void forms the basis
for this report.2. Materials and methods
2.1. Ampliﬁcation and cloning of the murine glucose transporter-2
promoter
Genomic DNA was obtained from the liver of a non-obese diabetic
(NOD) mouse (purchased from The Department of Pathology, Uni-
versity of Florida, Gainesville, FL, USA) using the DNeasy Tissue
Kit (Qiagen, Valencia, CA, USA). The region between 1311 to +49
of the murine glucose transporter-2 (GLUT2) promoter was PCR
ampliﬁed using primers synthesized by Geno-Mechanix (Alachua,
FL, USA) and designed according to the published murine GLUT2 se-
quence (Genbank Accession No. X78722). The primers used for PCR
ampliﬁcation were: forward primer MGL2-1311F: 5 0-CGACTC-
GATCCGTTGGCCTGTCAGCTTGC-3 0, and reverse primer:
MGL2-+49R: 5 0-TGTGTGGAATTGTCCTCTTAATCCAGGTCC-
TG-3 0. The 1.36 kb GLUT2 promoter was subsequently cloned into
pGEM-T Easy vector (Promega, Madison, WI, USA).2.2. Creation of rAAV constructs
To create both the rAAV2-GLUT2-luciferase (Luc)-enhanced
yellow ﬂuorescent protein (EYFP) and rAAV2-GLUT-FHPIB10 con-
structs modiﬁcations were made to the original rAAV2-HIP-Luc-
EYFP construct. The HIP-Luc-EYFP construct is an 8.2 kb plasmid
containing a 2096 bp region of the human insulin promoter (HIP) driv-
ing the luciferase and enhanced yellow ﬂuorescent protein gene
(EYFP), all ﬂanked by inverted terminal repeats in the backbone of re-
combinant adeno-associated virus-2 (rAAV2) [26]. For creation of the
GLUT2-Luc-EYFP construct, the rAAV2-HIP-Luc-EYFP plasmid
was digested with EcoR1 (Promega) to remove the HIP. The digested
plasmid was subsequently dephosphorylated by shrimp alkaline phos-
phatase (Promega). As previously indicated, the GLUT2 promoter was
cloned into pGEM-T Easy vector (Promega). For subsequent liga-
tion, we took advantage of a naturally occurring EcoR1 site located
at position 837 relative to transcriptional start site and an EcoR1 site
located within the pGEM-T Easy vector which produced an 886 bp
promoter segment. The GLUT-2 promoter was removed by an EcoR1
digestion and subsequently ligated into the rAAV2-HIP-LUC-EYFP
construct by T4 DNA Ligase (Gibco-BRL, Rockville, MD, USA) to
produce the rAAV2-GLUT2-Luc-EYFP construct.
The prk7.proinsulin.Ifur.IIfurB10 plasmids containing a 330 bp fur-
in-cleavable human preproinsulin cDNA was kindly provided by
Genentech [27]. The original endoprotease cleavage sites were modiﬁed
to allow for processing by an endogenous, golgi derived enzyme known
as furin. This would allow for the processing of mature, biologically
active insulin in cells that lack the appropriate speciﬁc endoproteases
known as PC2 and PC3 found in pancreatic b-cells. The prk7.proinsu-
lin.Ifur.IIfurB10 plasmid contains the cDNA of human preproinsulin
containing a naturally occurring polymorphism found in a subset of
patients with hyperproinsulinemia. This variant contains a single ami-
no acid polymorphism within the B chain that replaces the histidine at
position 10 with an aspartic acid. This polymorphism has been previ-
ously shown to allow for the 10–100-fold higher accumulation of insu-
lin in comparison to expression of native proinsulin [27].
To create the rAAV2-GLUT2-fHPIB10 construct, an XhoI site was
incorporated by PCR ampliﬁcation at the 3 0 end the preproinsulinB10
cDNA. The preproinsulinB10 cDNA fragment was removed by a
digestion with HindIII and XhoI and ligated into the previously di-
gested rAAV2-GLUT2-Luc-EYFP to create the rAAV2-GLUT2-
fHPIB10 construct.2.3. Sequencing
All rAAV constructs were sequenced by using the ABI Prism BigDye
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosys-
tems, Foster City, CA, USA). The sequencing was performed in the
Center for Mammalian Genetics DNA Sequencing Core Facilities at
the University of Florida.2.4. Virus production
Viral packaging, utilizing the AAV serotype 2 or 5 capsids and titer
determination was performed by the Powell Gene Therapy Center at
the University of Florida as previously described [28].
2.5. rAAV transduction
HepG2 human hepatoma cells were seeded the day before transduc-
tion in 24-well cell culture treated dishes (Becton Dickinson, Franklin
Lakes, NJ, USA) with custom made glucose-free MEM (GiboBRL)
containing 10% FBS (Cellgro), penicillin (100 U)/streptomycin
(100 lg/ml), and non-essential amino acids (1·) (GibcoBRL). Hepa-
toma cells were seeded at a concentration of 1.0 · 105 cells per dish.
On the day of transduction, hepatoma cells were transduced at an
MOI of 1000:1 relevant rAAV particles per cell in 1 ml of serum and
glucose-free media for 2 h at 37 C, 5% CO2. Two hour later, glu-
cose-free complete media containing 10% serum was added. Twenty-
four hour post-transduction, medium was removed and replaced with
fresh medium containing the appropriate concentration of glucose.
After 24 h, cells were washed twice with 1· PBS (Cellgro Mediatech)
and lysed in 200 ll of Passive Lysis Buﬀer (1·) (Promega). Luciferase
activity of the rAAV2 and pRL-TK constructs was measured
sequentially using the Dual-Luciferase Reporter Assay System (Prome-
ga). Luciferase activity was measured for 10 s following a 2 s delay
using a Monolight 3010 luminometer (Analytical Luminescence
Laboratory, San Diego, CA, USA). Promoter activity was determined
by dividing the rAAV2 luciferase activity by activity of the
promoterless plasmid of pGL-3 basic (Promega). Total protein concen-
tration of the cell lysate was measured using the BCA Protein Assay
Reagent Kit (Pierce Biotechnology, Rockford, IL, USA). Luciferase
expression is expressed as light units normalized to total protein
concentration.
2.6. Animal studies
All studies were performed on C57Bl/6 mice, housed in individual
cages, and exposed to 12-h cycles of light and dark. All animal and sur-
gical procedures were approved by the Institutional Animal Care and
Use Committees of the University of Florida College of Medicine. Ani-
mals were supplied with water and standard mouse chow ad libitum.
For induction of diabetes, mice were injected with streptozotocin
(STZ) intraperitoneally (i.p.) in a single dose of 200 mg/kg dissolved
in 0.01 M (pH 4.4) citrate buﬀer. Glucose was measured during non-
fasted conditions daily on blood extracted from the tail vein using a
glucose-oxidase based meter (One Touch II, Lifescan, Inc., Milpitas,
CA). The majority of STZ-treated mice developed diabetes within
three weeks and those mice were used for this current study. Diabetes
onset was deﬁned as two consecutive blood glucose values separated by
48 h greater than 200 mg/dl. To control initial hyperglycemia and al-
low time for transgenic expression, we implanted sustained-release bo-
vine insulin implants (Linbit, Linshin Canada, Inc., Scarborough,
Ontario) via a trocar into the subcutaneous nuchal tissue. Expected
bovine insulin release rate is approximately 0.1 U per 24 h. Surgical
anesthesia was achieved using inhaled isoﬂurane. We injected the
rAAV5-GLUT2-fHPIB10 virus into the hepatic portal vein of diabetic
mice that received the insulin implants, at a dose of 1 · 109 viral par-
ticles in 1 ml of 0.9% NaCl. Untreated mice did not receive viral injec-
tion or sham operation.2.7. Insulin and C-peptide measurement
Transgenic human insulin expression in mouse sera was collected
during non-fasted conditions and measured using the Human Endo-
crine Lincoplex Kit (Linco Research, Inc., St. Charles, MO, USA).
Manufacturers instructions were followed according to the supplied
protocol and performed as previously described [28]. Based on speciﬁ-
cations listed by the manufacturer, the lincoplex kit does not cross-re-
act with the implant released bovine insulin. In addition, human C-
peptide expression was evaluated by the 1-2-3 UltraSensitive C-peptide
ELISA (ALPCO, Windham, NH, USA).2.8. Statistical analysis
Data are expressed as means ± S.E. of the mean as calculated using
programs resident to Excel 2000 (Microsoft, Redmond, WA, USA).
Statistical analysis of data was collected with an ANOVA followed
by the Tukey post hoc test (Sigmastat for Windows version 2.03).
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In the current study, we attempted to evaluate the ability of
the murine GLUT2 promoter to regulate the production of
insulin in diabetic mice. We hypothesized that the murine
GLUT2 promoter represents a promising and novel candidate
for imparting regulated insulin production in particular be-
cause its native in vivo transcriptional regulation is coupled
to both glucose and insulin concentration [20,22,24]. We eval-
uated an 886 bp region (837 to +49, Gen Bank Accession
No. X78722) of the murine GLUT2 promoter for glucose-
responsive gene expression. The rAAV2-GLUT2-LucEYFP
construct was created to evaluate glucose-regulated promoter
activity via luciferase expression in transduced hepatoma cells
(Fig. 1A). For glucose-regulated transgenic human insulin pro-
duction, we assembled the rAAV2-GLUT2-fHPIB10 construct
(Fig. 1B).
We ﬁrst evaluated whether the rAAV2-GLUT2-LucEYFP
construct was capable of glucose-responsive gene expression
when transduced into liver-derived cells. HepG2 cells
(1 · 105) were transduced at a multiplicity of infection (MOI)
of 1000:1 viral particles per cell in the absence of glucose.
Twenty-four hour post-transduction, the cell culture medium
was removed and replaced with fresh medium containing
increasing concentrations of glucose. The cells were then har-
vested for ascertainment of luciferase expression 24 h post-
glucose stimulation, and the data corrected for total cellularEYFPGLUT-2ITR ITRPoly  ALUC
GLUT-2ITR ITRPoly  AFHPI-B10
A
B
Fig. 1. Diagram of the recombinant adeno-associated viral constructs.
(A) rAAV2-GLUT2-LucEYFP. (B) rAAV2-GLUT2-fHPIB10. ITR-
inverted terminal repeat, GLUT2, mouse glucose transporter-2 pro-
moter (886 bp); LUC-EYFP, luciferase and enhanced yellowﬂuorescent
fusion protein; Poly-A, polyadenylation signal; and fHPI-B10, furin




















Fig. 2. Glucose responsiveness of rAAV2-GLUT2-LucEYFP as determined b
MOI of 1000:1 viral particles per cell in a 24-well tissue culture plate in the ab
and cell culture media containing increasing concentrations of glucose was
activity is expressed as light units (LU) per lg of protein. Results are expre
construct tested in triplicate. * denotes signiﬁcant diﬀerence from rAAV2-Gprotein. Luciferase expression increased in a dose-dependent
manner with maximal expression at 22 mM glucose (Fig. 2).
A time-course experiment was performed to evaluate the
kinetics of GLUT2-driven luciferase expression. HepG2 cells
were transduced with rAAV2-GLUT2-Luc-EYFP at an MOI
of 1000:1 (Viral particle per cell) in 0 mM glucose. Medium
containing 22 mM glucose was added and cells were harvested
over a 24 h time period and measured for luciferase expression
at a doubling time interval starting at time 0 post-glucose stim-
ulation. A progressive increase in promoter activity was found
at all time points, but did not reach signiﬁcance until 8 h
(Fig. 3). Speciﬁcally, increases in promoter activity from the
0 mM glucose conditions subject to statistical signiﬁcance were
observed at 8 (2.6-fold), 16 (4.7-fold) and 24 h (8.1-fold) post-
glucose stimulation (P < 0.001).
We then investigated the eﬀect on blood glucose levels of
expressing the rAAV5-GLUT2-fHPIB10 virus in STZ-induced
diabetic mice. Treated mice were separated into two groups:
(1) rAAV5-GLUT2-fHPIB10 treated (G2-fHPI type 5)
(n = 6), and (2) untreated (UT) (n = 4). All mice in both groups
were diabetic prior to treatment with a mean glucose concen-
tration of P 298 mg/dl. All STZ-induced diabetic mice re-
ceived an insulin implant immediately prior to hepatic portal
vein delivery of virus to allow time for transgenic expression.
Hypoglycemia followed by death was observed in 33% (2/6)
of the G2-fHPI type 5 group. In surviving mice, glycemic levels
rapidly decreased in both groups with normoglycemia estab-
lished by day 2 (Fig. 4). Normoglycemia was maintained from
days 1 to 7 post-injection/implantation for both groups. How-
ever, UT mice had slightly higher glucose levels than the
G2-fHPI type 5 group. On day 15 when the insulin sustained-
release pellets were cleared, the UT group rapidly increased to
hyperglycemic levels (262.3 mg/dl ± 57.5 S.E.M.) whereas the
G2-fHPI type 5 treated mice remained euglycemic (100.3 mg/
dl ± 33.4 S.E.M.). The UT group exhibited persistent hyper-
glycemia from days 15 through 49. The G2-fHPI type 5 treated
mice had lowered blood glucose levels at all time points evalu-
ated post-insulin pellet clearance as compared to the untreated
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Fig. 3. Glucose stimulated time-course expression of HepG2 cells transduced by rAAV2-GLUT2-LucEYFP. HepG2 cells were transduced in
triplicate in a 24-well tissue culture plate at an MOI of 1000:1 in the absence of glucose. Twenty-four hour post-transduction media was completely
removed and fresh media was added containing 22 mM glucose. Cells were harvested at incremental time points post-glucose stimulation and
measured for luciferase expression. Promoter activity is expressed as mean fold above 0 mM glucose conditions ± S.E.M. from two independent
experiments with each construct tested in triplicate. * denotes statistically signiﬁcant diﬀerence from rAAV2-GLUT2-Luc-EYFP promoter activity at
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Fig. 4. Reduced hyperglycemia in diabetic mice following injection of rAAV5-GLUT2-fHPIB10 virus. C57Bl/6 mice were treated with streptozotocin
intraperitoneally (i.p.) in a single dose of 200 mg/kg dissolved in 0.01 M (pH 4.4) citrate buﬀer. Diabetic onset was deﬁned as two consecutive blood
glucose values greater than 200 mg/dl. After diabetic onset, mice were both implanted with sustained-release insulin implants and injected with the
viral constructs simultaneously and is denoted by day 1. The rAAV5-GLUT2-fHPIB10 (n = 4) viral constructs were injected into the hepatic portal
vein at a dose of 1.0 · 109 viral particles. Diabetic mock-injected mice (n = 4) received the insulin implant but no viral injection or sham operation
(Untreated). Non-fasting blood glucose levels were measured on blood extracted from the tail vein using a glucose-oxidase based meter (One Touch
II, Lifescan, Inc.). Mean glucose levels are shown. Error bars represent standard error of the mean (S.E.M.).
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were normoglycemic after 77 days post-injection (data not
shown). Blood glucose levels increased to approximately
250 mg/dl in the other G2-fHPI type 5 injected mice after ﬁve
weeks which is most likely the result of decreased transgenic
expression.
Our next objective was to determine if successful transgenic
delivery of hepatic insulin resulted in detectable levels of both
human insulin and C-peptide in the serum. Our prior studies
have conﬁrmed that the mouse lincoplex assay kit is capable
of detecting furin-cleavable human insulin in the media of
transfected HepG2 human hepatoma cells (data not shown).
All rAAV injected mice had detectable levels of both human
insulin and C-peptide (Table 1). As expected, serum from con-
trol UT mice did not test positive for either human insulin orC-peptide. Human insulin and C-peptide levels were typically
directly concordant which implies true de novo processing of
transgenic insulin. Levels of insulin from the G2-fHPI-Type
5 injected mice were very consistent (23 lIU/ml ± 1.9
S.E.M.), whereas C-peptide levels ranged from 24.6 to
231.8 ng/ml. In addition, the glycemic levels were also very
consistent with high human insulin measurements in the G2-
fHPI type 5 injected group.
The in vivo G2-fHPI-Type 5 injections did not result in gross
hypoglycemia in the surviving mice and the in vitro data dem-
onstrated that the GLUT2 promoter had decreased activity in
low to basal glucose conditions. These results support the po-
tential of the GLUT2 promoter being utilized in a therapeutic
role in the treatment of diabetes with regard to the avoidance
of induced hypoglycemia. However, further experiments need
Table 1
Blood glucose, insulin, and C-peptide levels at 28 days post-treatment
Treatment group N BG (mg/dl) Insulin (lIU/ml) C-peptide (ng/ml)
G2-fHPI-Type 5 1 146 23.5 191
2 150 22.6 24.6
3 97 18.4 67.1
4 105 27.5 231.8
UT 1 343 BD BD
2 330 BD BD
BG, blood glucose; BD, below detection; G2-fHPI-Type 5, refers to diabetic C57Bl/6 mice injected with rAAV5-GLUT2-fHPIB10 virus; UT refers to
diabetic C57Bl/6 mice that received insulin pellet with no injection (untreated). All measurements were obtained from tail blood samples of non-
fasted mice at 28 days after hepatic portal vein delivery of virus.
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this potential complication. In addition, dose-escalation stud-
ies are necessary to further determine the eﬃcacy of this trans-
genic insulin approach. Another potential therapeutic
limitation with HIGT is the onset of inﬂammation at the site
of injection. To address this, livers were removed and evalu-
ated from transduced mice by immunohistochemistry. Overall,
there was no indication of an inﬂammatory response (data not
shown). However, our study demonstrated that the glycemic
levels in the G2-fHPI Type 5-injected mice gradually began
to increase. This may be due to the possibility of an antibody
response to human insulin resulting in decreased transgenic
expression. We did not test for anti-human insulin antibodies
and will work towards their detection in future studies. Our re-
sults initially demonstrate that the GLUT2 promoter can be
utilized to regulate hepatic insulin production and potentially
control glucose levels in diabetic patients.Acknowledgments: The authors gratefully acknowledge Genentech,
Inc., for supplying the furin-cleavable human preprosinsulin cDNAs.
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